Biogen hopes for breakthrough at Danish Medicines Council after new price drop: "We have taken significant action"

In a video meeting on May 13, the Danish Medicines Council will discuss whether the use of drug Spinraza should be extended to a wider group of patients, after its creator Biogen has lowered the price significantly and new data has emerged.

Janne Harder, CEO of Biogen Denmark. | Photo: Biogen Danmark / PR

The Danish Medicines Council, which decides whether new medicines should be accepted for widespread use at Danish hospitals, will decide whether to expand the use of Spinraza (nusinersen) to more patients at a video meeting on May 13, the council reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs